The Venture Codex

Participated · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Participated · Series C · Jun 2026

CereVasc is a clinical-stage medical device company based in Massachusetts developing the eShunt System, an investigational, patented endovascularly implantable cerebrospinal fluid shunt and delivery components. The eShunt employs a percutaneous transvenous-transdural approach intended to enable a minimally invasive treatment for communicating hydrocephalus. The company is currently conducting the STRIDE pivotal trial, a prospective, multi-center, randomized, controlled study comparing the eShunt System to the standard ventriculo-peritoneal (VP) shunt to evaluate safety and effectiveness. Data from STRIDE are intended to support a future FDA Premarket Approval (PMA) submission. CereVasc describes the eShunt as investigational and not yet approved for commercial sale. The company plans to use recent Series C proceeds to complete the pivotal trial, advance regulatory work, scale operations, and prepare for U.S. commercialization.

Participated · Convertible Note · Mar 2026

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

Participated · Series D · Feb 2026

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on improving musculoskeletal health through innovative biologic treatments. Its pipeline currently features three clinical candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The company recently completed enrollment in its Phase 2 ARTEMIS trial of AGA2118 and has initiated dosing in the Phase 2 IDUN trial evaluating AGA2115. Proceeds from its latest financing will also advance these programs and other undisclosed pipeline assets. Headquartered in Westlake Village, California, Angitia leverages extensive bone biology expertise and rational drug design to address clear unmet medical needs in serious musculoskeletal diseases. No commercial products have been approved yet, reflecting the firm’s clinical-stage status.